These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 28474864)

  • 61. Endostar regulates EMT, migration and invasion of lung cancer cells through the HGF-Met pathway.
    Shen Y; Chen Q; Li L
    Mol Cell Probes; 2019 Jun; 45():57-64. PubMed ID: 31096000
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MET and phosphorylated MET as potential biomarkers in lung cancer.
    Tretiakova M; Salama AK; Karrison T; Ferguson MK; Husain AN; Vokes EE; Salgia R
    J Environ Pathol Toxicol Oncol; 2011; 30(4):341-54. PubMed ID: 22181983
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Dysregulation of HGF/c-Met signal pathway and their targeting drugs in lung cancer].
    Li Y; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):625-34. PubMed ID: 25130970
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
    Ahn SY; Kim J; Kim MA; Choi J; Kim WH
    Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
    [TBL] [Abstract][Full Text] [Related]  

  • 66. YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells.
    Jiang WG; Ye L; Ruge F; Owen S; Martin T; Sun PH; Sanders AJ; Lane J; Satherley L; Weeks HP; Gao Y; Wei C; Wu Y; Mason MD
    J Transl Med; 2015 Aug; 13():280. PubMed ID: 26310485
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models.
    Coxon A; Rex K; Meyer S; Sun J; Sun J; Chen Q; Radinsky R; Kendall R; Burgess TL
    Mol Cancer Ther; 2009 May; 8(5):1119-25. PubMed ID: 19435874
    [TBL] [Abstract][Full Text] [Related]  

  • 68. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
    Shojaei F; Simmons BH; Lee JH; Lappin PB; Christensen JG
    Cancer Lett; 2012 Jul; 320(1):48-55. PubMed ID: 22269210
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The emerging role of MET/HGF inhibitors in oncology.
    Scagliotti GV; Novello S; von Pawel J
    Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
    [TBL] [Abstract][Full Text] [Related]  

  • 70. MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.
    Casaletto JB; Geddie ML; Abu-Yousif AO; Masson K; Fulgham A; Boudot A; Maiwald T; Kearns JD; Kohli N; Su S; Razlog M; Raue A; Kalra A; Håkansson M; Logan DT; Welin M; Chattopadhyay S; Harms BD; Nielsen UB; Schoeberl B; Lugovskoy AA; MacBeath G
    Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7533-7542. PubMed ID: 30898885
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.
    Nishimura Y; Takiguchi S; Ito S; Itoh K
    Int J Oncol; 2014 Feb; 44(2):412-26. PubMed ID: 24297483
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Tumor microenvironment elicits primary resistance to afatinib through HGF secretion].
    Kang XH; Wang LF; Cao F; Fan FT; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):732-6. PubMed ID: 24378092
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
    Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
    Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
    J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Extracellular signal-regulated kinase and Akt activation play a critical role in the process of hepatocyte growth factor-induced epithelial-mesenchymal transition.
    Tanahashi T; Osada S; Yamada A; Kato J; Yawata K; Mori R; Imai H; Sasaki Y; Saito S; Tanaka Y; Nonaka K; Yoshida K
    Int J Oncol; 2013 Feb; 42(2):556-64. PubMed ID: 23229794
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.
    Gao CF; Xie Q; Zhang YW; Su Y; Zhao P; Cao B; Furge K; Sun J; Rex K; Osgood T; Coxon A; Burgess TL; Vande Woude GF
    Mol Cancer Ther; 2009 Oct; 8(10):2803-10. PubMed ID: 19825800
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer.
    Patel MB; Pothula SP; Xu Z; Lee AK; Goldstein D; Pirola RC; Apte MV; Wilson JS
    Carcinogenesis; 2014 Aug; 35(8):1891-900. PubMed ID: 24876152
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
    Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S
    J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
    [TBL] [Abstract][Full Text] [Related]  

  • 80. HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop.
    Syed ZA; Yin W; Hughes K; Gill JN; Shi R; Clifford JL
    BMC Cancer; 2011 May; 11():180. PubMed ID: 21595927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.